Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 14Fallopian Tube Neoplasms 8Uterine Cervical Neoplasms 3Pancreatic Neoplasms 2Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Fallopian Tube Mucinous Adenocarcinoma 1Ependymoma 1Endometrial Adenocarcinoma 1Choriocarcinoma 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

pembrolizumab 5Cyclophosphamide 4Carboplatin 4Filgrastim 3fludarabine 2Thiotepa 2Temozolomide 2Riluzole 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Peripheral Blood Stem Cell Transplantation 2Immunohistochemistry 2Drug Therapy 2Counseling 2Bupropion 2vofatamab 1utomilumab 1trastuzumab deruxtecan 1toripalimab 1tasquinimod 1sodium thiosulfate 1sargramostim 1saracatinib 1poly ICLC 1pertuzumab 1liposomal doxorubicin 1lenvatinib 1ixabepilone 1etoposide phosphate 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liver Neoplasms × cediranib × Gynecologic × Clear all
NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡